Abbott Laboratories remains a diversified global healthcare leader with strong cash flow generation and stable margins, though recent earnings volatility warrants close monitoring.
Abbott Laboratories is a diversified global healthcare company focused on diagnostics, medical devices, and nutrition businesses. The company has a cash-generative profile with a TTM operating cash flow of $9.57B and stable gross margins, with the most recent gross margin at 56.4%.
The company demonstrates steady top-line per‑share expansion: revenue per share grew 5.7% year‑over‑year most recently. Over the past five years, revenue‑per‑share CAGR is approximately 5.08%, and book value per share has compounded at about 9.72%, indicating consistent equity growth.
Investing and financing activities remain active, with TTM investing cash flow around –$2.42B and financing cash flow at –$6.31B.
Operational margins remain robust, with the latest operating margin near 28.6%.
There are notable weaknesses to monitor:
Key fundamentals to monitor include:
The recent P/E ratio of ~28.6x suggests market re‑rating dynamics are at play.
The foundation of business quality and long-term value creation
Abbott Laboratories’ revenue has shown a steady upward trend through 2025, rising from $10.36B in Q1 2025 to $11.14B in Q2, $11.37B in Q3 and $11.46B in Q4 2025. Over the multi-year series, revenue moved from the high single-digit billions in 2019–2021 into consistent low‑to‑mid‑$10B quarterly levels by 2024–2025, with the most recent reported revenue at $11.46B for the quarter ended 2025-12-31.
Net income is more variable than revenue across the same period. Excluding an unusually large net income of $9.23B in Q4 2024, quarterly net income generally ranged around $1.0B – $2.5B; recent quarters include $1.78B (2025-12-31), $1.64B (2025-09-30), $1.78B (2025-06-30) and $1.32B (2025-03-31), followed by $1.08B in the most recent quarter ended 2026-03-31. The most recent quarterly revenue was $11.46B. The most recent quarterly net income was $1.08B.
Why Growth Matters
Consistent revenue and earnings growth are the lifeblood of successful long-term investments. Companies that can grow their top line (revenue) and bottom line (net income) over many years demonstrate they have products or services customers value and are willing to pay for repeatedly.
Revenue Growth shows whether the company is expanding its market reach, gaining market share, or successfully launching new products.Net Income Growth demonstrates the company can convert that revenue into actual profits while managing costs effectively.
Look for steady, sustainable growth rather than erratic spikes. The best businesses compound earnings year after year, creating tremendous value for shareholders over time. Companies that can grow earnings faster than revenue are improving their profitability—a sign of operational excellence and competitive strength.
Year-over-year growth rates for revenue and earnings per share
Reading the Growth Rate Chart
This chart converts the absolute per-share figures into year-over-year percentage changes, making it easy to see whether growth is accelerating, decelerating, or reverting to trend — regardless of the company's absolute size.
Revenue per Share Growth (1-year, split-adjusted) measures how quickly the top line is expanding on a per-share basis. Sustained positive growth signals that the company continues to win customers and grow its addressable market.EPS Diluted Growth (1-year, split-adjusted) measures how quickly earnings are compounding for each shareholder. When EPS growth consistently outpaces revenue growth, operating leverage and margin expansion are at work.
Look for consistency, not just magnitude. A company that reliably grows EPS 10–15% per year is far more valuable than one that alternates between 50% spikes and deep contractions. Negative EPS growth during a period of positive revenue growth is a red flag — costs are rising faster than sales. Quarters where both lines converge near zero or go negative deserve close scrutiny.
How revenue converts to net income for the most recent annual period
Over the period Jan 2025 to Dec 2025, Abbott Laboratories converts approximately 56¢ of every revenue dollar into gross profit (gross margin: 56.4%).After accounting for operating expenses and taxes and expenses, the company retains 14.7% as net profit margin, resulting in $6.52B in net earnings.
Period Information
Report Type: Annual (10-K)
Period: Jan 2025 to Dec 2025
Analyzing long-term margin stability and competitive positioning
Abbott Laboratories' gross margin has been relatively stable in the mid-50s over the period shown, dipping into the low-55% range in 2023 and then recovering modestly through 2024–2025 to 56.4% in the most recent quarter. Operating margin shows a clear decline from a 2021–2022 peak in the low-30% range to the high-20s in 2023, followed by a gradual recovery over the last year; the most recent operating margin is 28.6%. These two margins reflect a stable gross profitability profile with operating profitability still below its 2021–2022 highs but improving recently.
Net profit margin exhibits the largest volatility: it hovered in the mid-teens through 2021–mid‑2023, then jumped to about 31–32% across late‑2024 and most of 2025 before dropping sharply in the latest quarter to 14.7%. That late‑2025 decline is a notable inflection point relative to the elevated net margins earlier in 2025. The most recent gross margin was 56.4%, the most recent operating margin was 28.6%, and the most recent net profit margin was 14.7%.
Understanding Profit Margins
Between Jan 2025 and Dec 2025, Abbott Laboratories converts every dollar of revenue through the following stages:
Sustainable competitive advantages reveal themselves through consistently superior profit margins over extended periods. Companies with durable economic moats maintain pricing power and operational efficiency that competitors struggle to match.
A sign of durable competitive advantage is earning sustained higher margins than competitors.Look for margins that remain stable or improve over time, especially during economic downturns. Declining margins may signal increasing competition, pricing pressure, or deteriorating business fundamentals.
Comparing reported earnings to actual cash generation
ABBOTT LABORATORIES' operating cash flow (TTM) has been relatively stable in the high single-digit billions while net income (TTM) has shown larger swings. Operating cash flow ran roughly between $7B and $10.5B across the multi-year series and climbed through 2025 to about $9.57B (period ending 2025-12-31). Net income was generally in the $5–8B range before 2025, rose sharply to about $13.4–13.98B across early-to-mid 2025, and then declined to lower levels by late 2025 and early 2026.
The key inflection occurred in mid-2025 when reported net income materially exceeded operating cash flow (net income ~ $13.5–14.0B versus operating cash flow near $9.0B), creating a pronounced earnings-versus-cash gap. In the most recent TTM comparison that gap has reversed: operating cash flow remained near $9.6B while net income fell to roughly $6.3B. The most recent Net Income (TTM) was $6.28B (period ending 2026-03-31) and the most recent Operating Cash Flow (TTM) was $9.57B (period ending 2025-12-31).
The Earnings vs. Cash Flow Gap
Reported earnings (Net Income) doesn't always reflect actual cash generation. Companies use accrual accounting, which recognizes revenue when earned and expenses when incurred—not when cash actually changes hands. This creates timing differences and opportunities for accounting discretion that can mask underlying business health.
Net Income (the "earnings" number) can be influenced by non-cash items like depreciation, stock-based compensation, and changes in accounting estimates.Operating Cash Flow, however, shows the actual cash the business generates from its core operations—a harder number to manipulate.
Trailing Twelve Months
What to Look For
Key Insight: Companies with durable competitive advantages typically show operating cash flow that meets or exceeds net income over time, demonstrating they convert accounting profits into actual cash that can be returned to shareholders or reinvested in the business.
Measuring management's efficiency at generating profits from shareholder capital
ABBOTT LABORATORIES' return on equity was broadly stable and elevated through 2024 and most of 2025, registering in the high-20s (28.1% on 2024-12-31; 27.7% on 2025-03-31; 27.6% on 2025-06-30; 27.4% on 2025-09-30). A clear inflection occurred in the most recent two quarters, with ROE falling to 12.5% on 2025-12-31 and edging down further to 12.1% on 2026-03-31.
In historical context, ROE for ABBOTT LABORATORIES spent much of 2022–2024 in the mid-teens and earlier years showed greater variability, including peaks above 20% in several periods. The current level of 12.1% is below the 15–20% range noted in the chart background as generally considered strong. The most recent Return on Equity was 12.1%.
The Gold Standard of Profitability
Return on Equity (ROE) is a powerful measure of how effectively a company's management is using the money shareholders have invested. Calculated by dividing Net Income by Shareholders' Equity, it reveals how much profit is generated for every dollar of equity capital.
A consistently high ROE (typically above 15-20%) is often the signature of a "quality" business with a durable competitive advantage. It indicates that the company can generate high returns on its own capital, which it can then reinvest at these high rates to compound value over time.
What to Look For:
How the company generates and deploys its cash
Over the past several years ABBOTT LABORATORIES' operating cash flow TTM showed a clear down‑then‑up pattern: it fell from peaks above $10B in 2021 to a trough around $6.55B in 2023‑09, then recovered through 2024–2025 to $9.57B by 2025‑12‑31. Investing cash flow has been consistently negative, with larger outflows near -$3.1B in late 2023 and early 2024 that moderated to a more stable range around -$2.3B to -$2.5B in recent quarters. Financing cash flow has remained negative throughout the period, with the largest outflows in early 2022 (around -$8.3B) and more moderate but still substantial outflows in 2024–2025.
Recent quarterly TTM values show operating cash recovering toward pre‑trough levels while investing outflows have steadied and financing outflows remain material. The most recent trailing twelve‑month operating cash flow was $9.57B, investing cash flow was -$2.42B, and financing cash flow was -$6.31B.
Understanding Company Strategy
Capital allocation refers to how management decides to spend and invest the company's cash. Analyzing the three primary categories of cash flow reveals a company's true operational strategy:
What to look for: Is the company bootstrapping (funding growth solely from operating cash)? Are they borrowing to fund aggressive expansion or dividends? Or are they capital raising by issuing new shares, potentially diluting your ownership? A healthy, mature company typically generates strong operating cash, moderately invests in growth, and returns the surplus to shareholders through financing activities.
Trailing Twelve Months
Net assets attributable to each share — the accounting floor of intrinsic value
Why Book Value per Share Matters
Book value per share is the net worth of the company — total assets minus total liabilities — divided by shares outstanding (split-adjusted). It represents the theoretical liquidation value per share if every asset were sold and every liability repaid at balance-sheet carrying values. It is the accounting foundation upon which much of equity valuation is built.
A steadily rising book value per share is one of the most reliable signals of compounding wealth creation. It means the company is retaining earnings and building net worth faster than it is returning capital or eroding it. Warren Buffett famously tracked Berkshire Hathaway's book value per share for decades as his primary measure of intrinsic value growth.
Context is essential. Asset-heavy businesses (banks, manufacturers, utilities) should be judged by book value more directly than asset-light businesses (software, consumer brands), where intangible assets like intellectual property and customer loyalty may far exceed their balance-sheet carrying values. A company trading at a large premium to book value is not necessarily overvalued — it may simply possess competitive advantages that accounting rules do not capture. Conversely, a declining book value per share — especially over multiple years — is a serious warning sign of capital destruction.
How much of the company is financed by debt versus shareholders' equity
Reading the Debt-to-Equity Ratio
The debt-to-equity (D/E) ratio compares total financial debt to shareholders' equity. A ratio of 1.0 means the company has borrowed one dollar for every dollar of equity; a ratio of 2.0 means it has borrowed twice as much as it owns. Financial leverage amplifies both returns and risk: in good times, debt turbocharges equity returns; in bad times, it accelerates losses and can threaten solvency.
Trends matter more than a single number. A rising D/E ratio can mean the company is taking on debt to fund growth — potentially value-creating if returns exceed the cost of capital. But it can also mean equity is being eroded through losses or that the business is borrowing simply to sustain operations. A falling D/E ratio generally reflects strengthening financial health: earnings are being retained, debt maturities are being paid down, or both.
Industry norms vary enormously. Capital-intensive sectors (utilities, real estate, financials) routinely carry high D/E ratios that would be alarming in, say, a technology company. Always compare against sector peers. As a rough rule of thumb, a D/E above 2× in a cyclical business warrants careful scrutiny of interest coverage and refinancing risk.
Short-term liquidity — can the company cover its near-term obligations?
Liquidity: Can the Business Pay Its Bills?
The current ratio is calculated as current assets divided by current liabilities. A ratio of 1.5 means the company has $1.50 of short-term assets — cash, receivables, inventory — for every $1.00 of obligations due within the next twelve months. It is the most direct measure of near-term financial resilience: can the business meet its obligations without needing to raise new capital or sell long-term assets at a discount?
A ratio above 1.0 is generally healthy, meaning current assets exceed current liabilities. A ratio consistently above 2.0 may indicate the company is holding excess cash or inventory that could be deployed more productively. A ratio below 1.0 is a warning sign — the company is relying on future cash generation or external financing to cover its near-term obligations, which is manageable in normal conditions but dangerous during a downturn.
Trends and context matter.A declining current ratio isn't always alarming — highly efficient businesses (e.g., large retailers with reliable daily cash flows) often run leaner balance sheets intentionally. Conversely, a rapidly rising current ratio can signal slowing sales causing inventory to build, or customers taking longer to pay. Always compare the trend against industry peers and cross-reference with the cash flow statement to assess whether the business is genuinely liquid or just holding non-cash current assets.
How much the market is paying for each dollar of company earnings
ABBOTT LABORATORIES’ trailing twelve-month P/E showed a meaningful inflection in late 2024 and through 2025. After trading in the mid-30s in mid‑2024 (32.5x–34.6x), the ratio dropped sharply to 14.8x at 2024-12-31 and then held around 16–17x through the first three quarters of 2025. The metric re‑rated higher in Q4 2025 to 33.6x before easing to 28.6x in the most recent quarter.
Over the longer term the P/E has been volatile, with very large spikes in 2017–2018 (peaks above 200x) and elevated readings through 2019–2021 (notably 56.3x in 2020-09). More recently the series moved from mid‑30s in early 2023 into the low‑teens/teens range in late 2024–2025, then back up in late 2025 and slightly down in Q1 2026. The most recent quarterly P/E ratio for ABBOTT LABORATORIES was 28.6x.
What Is the PE Ratio?
The Price-to-Earnings (PE) ratio is one of the most widely used valuation metrics in investing. It divides the current stock price by the company's earnings per share (EPS), revealing how much investors are willing to pay for each dollar of earnings. A high PE can signal that the market expects strong future growth, while a low PE may suggest undervaluation—or reflect genuine concerns about the company's prospects.
Context matters:PE ratios vary significantly across industries. High-growth technology companies routinely trade at PE ratios above 30x or 40x, while mature, low-growth sectors like utilities or financials often trade closer to 10–15x. Always compare a company's PE to its own history and its industry peers, not just an absolute number.
What to Look For:
Key Insight:The PE ratio is a snapshot of market sentiment and expectations. Tracking it over time alongside earnings trends reveals whether the market's valuation has expanded or contracted—and whether that change is justified by fundamentals.